drugset / Trial / NCT03208218
Crossover Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap in Healthy Male Volunteers
Phase 1
Completed
42 enrolled
Samyang Biopharmaceuticals Corporation
Chungnam National University Hospital · collab
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to evaluate the pharmacokinetics equivalence and safety by comparing pharmacokinetics characteristics between the SYP-1512 Tab and Revlimid cap (25mg) when administered a single-dose to healthy male volunteers.
Timeline
- Start
- 2016-08-17
- Primary completion
- 2016-08-25
- Completion
- 2016-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |
Indications
No indication recorded.